Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology

A second reference standard in the surgical and nonsurgical treatment of low-grade gliomas

Meng Law, Sarah K. Oh, Glyn Johnson, James S. Babb, David Zagzag, John Golfinos, Patrick J. Kelly

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

OBJECTIVE: To determine whether relative cerebral blood volume (rCBV) can predict patient outcome, specifically tumor progression, in low-grade gliomas (LGGs) and thus provide a second reference standard in the surgical and postsurgical management of LGGs. METHODS: Thirty-five patients with histologically diagnosed LGGs (21 low-grade astrocytomas and 14 low-grade oligodendrogliomas and low-grade mixed oligoastrocytomas) were studied with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging. Wilcoxon tests were used to compare patients in different response categories (complete response, stable, progressive, death) with respect to baseline rCBV. Log-rank tests were used to evaluate the association of rCBV with survival and time to progression. Kaplan-Meier time-to-progression curves were generated. Tumor volumes and CBV measurements were obtained at the initial examination and again at follow-up to determine the association of rCBV with tumor volume progression. RESULTS: Wilcoxon tests showed patients manifesting an adverse event (either death or progression) had significantly higher rCBV (P = 0.003) than did patients without adverse events (complete response or stable disease). Log-rank tests showed that rCBV exhibited a significant negative association with disease-free survival (P = 0.0015), such that low rCBV values were associated with longer time to progression. Kaplan-Meier curves demonstrated that lesions with rCBV less than 1.75 (n = 16) had a median time to progression of 4620 ± 433 days, and lesions with rCBV more than 1.75 (n = 19) had a median time to progression of 245 ± 62 days (P < 0.005). Lesions with low baseline rCBV (<1.75) demonstrated stable tumor volumes when followed up over time, and lesions with high baseline rCBV (>1.75) demonstrated progressively increasing tumor volumes over time. CONCLUSION: Dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging may be used to identify LGGs that are either high-grade gliomas, misdiagnosed because of sampling error at pathological examination or that have undergone angiogenesis in the progression toward malignant transformation. This suggests that rCBV measurements may be used as a second reference standard to determine the surgical management/risk - benefit equation and postsurgical adjuvant therapy for LGGs.

Original languageEnglish (US)
Pages (from-to)1099-1107
Number of pages9
JournalNeurosurgery
Volume58
Issue number6
DOIs
StatePublished - Jun 2006
Externally publishedYes

Fingerprint

Magnetic Resonance Angiography
Glioma
Tumor Burden
Therapeutics
Astrocytoma
Cerebral Blood Volume
Oligodendroglioma
Selection Bias
Diagnostic Errors
Disease-Free Survival
Survival

Keywords

  • Brain
  • Low-grade gliomas
  • Perfusion magnetic resonance imaging
  • Survival

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology : A second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. / Law, Meng; Oh, Sarah K.; Johnson, Glyn; Babb, James S.; Zagzag, David; Golfinos, John; Kelly, Patrick J.

In: Neurosurgery, Vol. 58, No. 6, 06.2006, p. 1099-1107.

Research output: Contribution to journalArticle

Law, Meng ; Oh, Sarah K. ; Johnson, Glyn ; Babb, James S. ; Zagzag, David ; Golfinos, John ; Kelly, Patrick J. / Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology : A second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. In: Neurosurgery. 2006 ; Vol. 58, No. 6. pp. 1099-1107.
@article{b337a21ef5164b0db562b3b8dfaf00c4,
title = "Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: A second reference standard in the surgical and nonsurgical treatment of low-grade gliomas",
abstract = "OBJECTIVE: To determine whether relative cerebral blood volume (rCBV) can predict patient outcome, specifically tumor progression, in low-grade gliomas (LGGs) and thus provide a second reference standard in the surgical and postsurgical management of LGGs. METHODS: Thirty-five patients with histologically diagnosed LGGs (21 low-grade astrocytomas and 14 low-grade oligodendrogliomas and low-grade mixed oligoastrocytomas) were studied with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging. Wilcoxon tests were used to compare patients in different response categories (complete response, stable, progressive, death) with respect to baseline rCBV. Log-rank tests were used to evaluate the association of rCBV with survival and time to progression. Kaplan-Meier time-to-progression curves were generated. Tumor volumes and CBV measurements were obtained at the initial examination and again at follow-up to determine the association of rCBV with tumor volume progression. RESULTS: Wilcoxon tests showed patients manifesting an adverse event (either death or progression) had significantly higher rCBV (P = 0.003) than did patients without adverse events (complete response or stable disease). Log-rank tests showed that rCBV exhibited a significant negative association with disease-free survival (P = 0.0015), such that low rCBV values were associated with longer time to progression. Kaplan-Meier curves demonstrated that lesions with rCBV less than 1.75 (n = 16) had a median time to progression of 4620 ± 433 days, and lesions with rCBV more than 1.75 (n = 19) had a median time to progression of 245 ± 62 days (P < 0.005). Lesions with low baseline rCBV (<1.75) demonstrated stable tumor volumes when followed up over time, and lesions with high baseline rCBV (>1.75) demonstrated progressively increasing tumor volumes over time. CONCLUSION: Dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging may be used to identify LGGs that are either high-grade gliomas, misdiagnosed because of sampling error at pathological examination or that have undergone angiogenesis in the progression toward malignant transformation. This suggests that rCBV measurements may be used as a second reference standard to determine the surgical management/risk - benefit equation and postsurgical adjuvant therapy for LGGs.",
keywords = "Brain, Low-grade gliomas, Perfusion magnetic resonance imaging, Survival",
author = "Meng Law and Oh, {Sarah K.} and Glyn Johnson and Babb, {James S.} and David Zagzag and John Golfinos and Kelly, {Patrick J.}",
year = "2006",
month = "6",
doi = "10.1227/01.NEU.0000215944.81730.18",
language = "English (US)",
volume = "58",
pages = "1099--1107",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology

T2 - A second reference standard in the surgical and nonsurgical treatment of low-grade gliomas

AU - Law, Meng

AU - Oh, Sarah K.

AU - Johnson, Glyn

AU - Babb, James S.

AU - Zagzag, David

AU - Golfinos, John

AU - Kelly, Patrick J.

PY - 2006/6

Y1 - 2006/6

N2 - OBJECTIVE: To determine whether relative cerebral blood volume (rCBV) can predict patient outcome, specifically tumor progression, in low-grade gliomas (LGGs) and thus provide a second reference standard in the surgical and postsurgical management of LGGs. METHODS: Thirty-five patients with histologically diagnosed LGGs (21 low-grade astrocytomas and 14 low-grade oligodendrogliomas and low-grade mixed oligoastrocytomas) were studied with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging. Wilcoxon tests were used to compare patients in different response categories (complete response, stable, progressive, death) with respect to baseline rCBV. Log-rank tests were used to evaluate the association of rCBV with survival and time to progression. Kaplan-Meier time-to-progression curves were generated. Tumor volumes and CBV measurements were obtained at the initial examination and again at follow-up to determine the association of rCBV with tumor volume progression. RESULTS: Wilcoxon tests showed patients manifesting an adverse event (either death or progression) had significantly higher rCBV (P = 0.003) than did patients without adverse events (complete response or stable disease). Log-rank tests showed that rCBV exhibited a significant negative association with disease-free survival (P = 0.0015), such that low rCBV values were associated with longer time to progression. Kaplan-Meier curves demonstrated that lesions with rCBV less than 1.75 (n = 16) had a median time to progression of 4620 ± 433 days, and lesions with rCBV more than 1.75 (n = 19) had a median time to progression of 245 ± 62 days (P < 0.005). Lesions with low baseline rCBV (<1.75) demonstrated stable tumor volumes when followed up over time, and lesions with high baseline rCBV (>1.75) demonstrated progressively increasing tumor volumes over time. CONCLUSION: Dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging may be used to identify LGGs that are either high-grade gliomas, misdiagnosed because of sampling error at pathological examination or that have undergone angiogenesis in the progression toward malignant transformation. This suggests that rCBV measurements may be used as a second reference standard to determine the surgical management/risk - benefit equation and postsurgical adjuvant therapy for LGGs.

AB - OBJECTIVE: To determine whether relative cerebral blood volume (rCBV) can predict patient outcome, specifically tumor progression, in low-grade gliomas (LGGs) and thus provide a second reference standard in the surgical and postsurgical management of LGGs. METHODS: Thirty-five patients with histologically diagnosed LGGs (21 low-grade astrocytomas and 14 low-grade oligodendrogliomas and low-grade mixed oligoastrocytomas) were studied with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging. Wilcoxon tests were used to compare patients in different response categories (complete response, stable, progressive, death) with respect to baseline rCBV. Log-rank tests were used to evaluate the association of rCBV with survival and time to progression. Kaplan-Meier time-to-progression curves were generated. Tumor volumes and CBV measurements were obtained at the initial examination and again at follow-up to determine the association of rCBV with tumor volume progression. RESULTS: Wilcoxon tests showed patients manifesting an adverse event (either death or progression) had significantly higher rCBV (P = 0.003) than did patients without adverse events (complete response or stable disease). Log-rank tests showed that rCBV exhibited a significant negative association with disease-free survival (P = 0.0015), such that low rCBV values were associated with longer time to progression. Kaplan-Meier curves demonstrated that lesions with rCBV less than 1.75 (n = 16) had a median time to progression of 4620 ± 433 days, and lesions with rCBV more than 1.75 (n = 19) had a median time to progression of 245 ± 62 days (P < 0.005). Lesions with low baseline rCBV (<1.75) demonstrated stable tumor volumes when followed up over time, and lesions with high baseline rCBV (>1.75) demonstrated progressively increasing tumor volumes over time. CONCLUSION: Dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging may be used to identify LGGs that are either high-grade gliomas, misdiagnosed because of sampling error at pathological examination or that have undergone angiogenesis in the progression toward malignant transformation. This suggests that rCBV measurements may be used as a second reference standard to determine the surgical management/risk - benefit equation and postsurgical adjuvant therapy for LGGs.

KW - Brain

KW - Low-grade gliomas

KW - Perfusion magnetic resonance imaging

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=33745114332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745114332&partnerID=8YFLogxK

U2 - 10.1227/01.NEU.0000215944.81730.18

DO - 10.1227/01.NEU.0000215944.81730.18

M3 - Article

VL - 58

SP - 1099

EP - 1107

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 6

ER -